Organogenesis Holdings Inc. (ORGO)
ORGO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.21
-1.63% on the day
Market cap
$155.7M
Micro cap
Revenue · 2025
$564.2M
+17.0% on 2024
Net income · 2025
$37.0M
6.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ORGO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001661181 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $564.2M |
| Net income | $37.0M |
| Operating income | $44.7M |
| Net margin | 6.6% |
| Operating margin | 7.9% |
| Revenue growth | +17.0% |
| Cash | $93.7M |
| Total assets | $598.7M |
| P/E (computed) | 4.2× |
| P/S (computed) | 0.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-06 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 671 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MENS | Jyong Biotech Ltd. | $2.04 | -2.86% | $155.1M |
| DERM | Journey Medical Corporation | $5.68 | -3.89% | $160.3M |
| CNTN | Canton Strategic Holdings Inc. | $2.02 | -4.26% | $161.0M |
| NKTX | Nkarta Inc. | $2.10 | -3.23% | $150.4M |
| MSLE | Satellos Bioscience Inc. | $7.04 | -1.81% | $149.4M |
| ADAG | Adagene Inc. | $2.46 | -10.22% | $162.5M |
| NBP | NovaBridge Biosciences | $1.29 | -2.27% | $148.8M |
| VRXA | Veraxa Biotech AG | $1.20 | +5.26% | $169.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier